Valproate, a Mood Stabilizer, Induces WFS1 Expression and Modulates Its Interaction with ER Stress Protein GRP94 by Kakiuchi, Chihiro et al.
Valproate, a Mood Stabilizer, Induces WFS1 Expression
and Modulates Its Interaction with ER Stress Protein
GRP94
Chihiro Kakiuchi
1,3, Shinsuke Ishigaki
1, Christine M. Oslowski
1, Sonya G. Fonseca
1, Tadafumi Kato
3,
Fumihiko Urano
1,2*
1Program in Gene Function and Expression, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 2Program in Molecular
Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 3RIKEN Brain Science Institute, Wako, Saitama, Japan
Abstract
Background: Valproate is a standard treatment for bipolar disorder and a first-line mood stabilizer. The molecular
mechanisms underlying its actions in bipolar disorder are unclear. It has been suggested that the action of valproate is
linked to changes in gene expression and induction of endoplasmic reticulum (ER) stress-response proteins.
Principal Findings: Here we show that valproate modulates the ER stress response through the regulation of WFS1, an
important component for mitigating ER stress. Therapeutic concentrations of valproate induce expression of WFS1 mRNA
and activate the WFS1 promoter. In addition, WFS1 forms a complex with GRP94, an ER stress-response protein, in which
valproate dose-dependently enhances its dissociation from GRP94.
Conclusions: These results suggest that the therapeutic effects of valproate in bipolar disorder may be mediated by WFS1
expression and its dissociation from GRP94.
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Introduction
Bipolar disorder is a severe mental disorder characterized by
recurrent episodes of mania and depression, affecting about 0.5–
1% of the population [1]. Although the pathogenesis of bipolar
disorder is unclear, it is known that mood stabilizers, such as
valproate, can prevent its recurrence [2]. Valproate, a simple
branched-chain fatty acid, has been used in the treatment of
bipolar disorder, epilepsy, and migraine [3,4,5]. Valproate
increases the level of the inhibitory neurotransmitter c-aminobu-
tyric acid (GABA), with acute administration causing a 15%–45%
increase in GABA in the brains of rodents. Because inhibition of
GABAergic signaling can cause seizures and potentiation of
GABA signaling can prevent seizures, this effect of valproate on
GABA levels has been proposed as a mechanism for its
anticonvulsant activity [3,4,5].
The molecular mechanisms of valproate in bipolar disorder are
unclear. One hypothesis is that the therapeutic effect of valproate
in bipolar disorder may be mediated by changes in expression of
neuroprotective genes. Valproate increases the DNA binding of
activator protein 1 (AP-1), a transcription factor which is a
heterodimeric protein composed of proteins belonging to the c-
Fos, c-Jun, and ATF families [6,7]. This may lead to enhanced
expression of AP-1 target genes that have important functions in
neurons. In addition, valproate has been characterized as a histone
deacetylases (HDAC) inhibitor and can regulate gene expression
through epigenetic mechanisms [8]. These findings suggest an
attractive possibility that valproate increases expression of multiple
genes that have protective effects against bipolar disorder.
The unfolded protein response (UPR) is a gene expression
program that modulates endoplasmic reticulum (ER) stress, a
specific type of cell stress caused by the accumulation of misfolded
proteins in the ER [9,10]. GRP94 is a component of the UPR and
has a function in protein folding and degradation [11,12,13].
Genetic variations in the GRP94 gene are associated with bipolar
disorder in the Japanese population [14]. High throughput
proteomics analysis revealed that GRP94 interacts with WFS1
protein (Fonseca and Urano, unpublished data). WFS1 is also a
component of the UPR and regulates cellular ER stress levels [15].
WFS1 was initially identified as a causative gene for Wolfram
syndrome, a rare autosomal recessive disorder characterized by
diabetes insipidus, diabetes mellitus, optic atrophy and deafness
[16,17,18]. About 60% of patients with Wolfram syndrome have
some mental disturbance such as severe depression and psychosis
[19]. Importantly, even the heterozygotes who do not have
Wolfram syndrome are 26-fold more likely than non-carriers to
have a psychiatric hospitalization [20], and the relative risk of
psychiatric hospitalization for depression was estimated to be 7.1
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4134Figure 1. Valproate increases the expression of WFS1 without inducing other ER stress markers. (A) Neuro-2a cells were treated with
valproate (VPA, 100ug/ml) or lithium (Li, 1mM) for 4 hr, 24 hr, and 48 hr. Expression levels of Wfs1, phospho-eIF2a (P-eIF2a) and Actin were measured by
immunoblot. The relative amounts of the proteins, Wfs1 and P-eIF2a, which are adjusted by the amount of actin, are shown in the right panels. (B)
Expression levels of Wfs1, GRP94, GRP78, total Xbp-1, spliced Xbp-1, and Aatf were measured by quantitative real-time PCR (n=3; values are mean6SD).
doi:10.1371/journal.pone.0004134.g001
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WFS1 and GRP94 may be involved in bipolar disorder.
Here we show that valproate regulates WFS1 and GRP94 in
neurons. Valproate activates the WFS1 promoter and induces
WFS1 mRNA expression in neuronal cells. Under normal
conditions, WFS1 forms a complex with GRP94 and valproate
enhances its dissociation from GRP94. Our data raise the
possibility that the therapeutic effects of valproate in bipolar
disorder may be mediated by the modulation of ER stress through
the regulation of WFS1 and GRP94.
Results
Valproate increases the expression of WFS1 without
inducing other ER stress markers
To investigate the possible involvement of valproate in WFS1
functioninneurons,wefirstdeterminedexpressionlevelsofWFS1in
neuronal cell lines treated with a therapeutic concentration of
valproate. Valproate increased WFS1 protein expression levels in
Neuro-2a cells with a peak at 24 hr (Figure 1A, upper panel).
Another mood stabilizer, lithium, did not increase WFS1 expression
levels significantly in these cells (Figure 1A, lower panel).
WFS1 expression is regulated by the master regulators of ER
stress signaling, PERK and IRE1a, under ER stress conditions
[15]. To determine whether PERK signaling is involved in WFS1
upregulation by valproate, we measured expression levels of
phosphorylated eIF2a, which reflect PERK activation levels.
Valproate did not increase eIF2a phosphorylation levels (Figure 1A
upper panel), raising the possibility that WFS1 upregulation by
valproate is not regulated by the ER stress signaling network. To
test this idea, we measured mRNA expression levels of common
ER stress response genes, GRP94, GRP78, total and spliced XBP-
1, and AATF by real-time PCR. Figure 1B shows that expression
levels of these ER stress markers did not change by valproate,
indicating that valproate specifically upregulates WFS1 without
activating other components of ER stress signaling.
It has been proposed that WFS1 mRNA expression is regulated
by a 500-base-pair promoter region located upstream of its
transcriptional start site [22]. We were therefore interested in
determining whether this WFS1 promoter can be activated by
valproate treatment. We transfected a neuronal cell line, SH-SY5Y
cells, with a reporter plasmid containing 500 bases of the WFS1
promoter driving the luciferase gene or a control reporter plasmid
containing only 60 bases of the WFS1 promoter, then treated these
cells with two different concentrations of valproate. Valproate led to
a seven fold (50 mg/ml) and a twelve fold (200 mg/ml) induction of
luciferaseactivity(Figure 2,lanes 4and 5).The samepromotercould
not be activated in non-neuronal 293T cells (data not shown). It has
been postulated that XBP-1 is important in activating the WFS1
promoter in SH-SY5Y cells [22]. We therefore considered the
possibility that the addition of valproate to XBP-1 expression can
enhance luciferease activity. To test this idea, we co-transfected SH-
SY5Y cells with XBP-1 expression plasmid along with the WFS1
reporter plasmid or the control plasmid with or without valproate
treatment. As we predicted, the addition of valproate enhanced the
induction of luciferase activity by XBP-1 in a dose-dependent
manner (Figure 2, lanes 7 and 8). Collectively, these results indicate
that valproate can strongly activate the WFS1 promoter together
with XBP-1 specifically in neuronal cells.
Mood stabilizers modulate WFS1-GRP94 complex
High-throughput proteomics analysis has shown that WFS1
interacts with GRP94 (Fonseca and Urano, manuscript in
preparation). To confirm this, we examined the association of
WFS1 with GRP94 in Neuro-2a cells by immunoprecipitation. As
we predicted, WFS1 associated with GRP94 under normal
conditions (Figure 3A, lane 2, upper panels, IP).
It has been shown that valproate and lithium can modulate
GRP94 expression in neurons [23], raising the possibility that this
interaction can also be modulated with valproate and lithium. To
test this possibility, we treated Neuro-2a cells with therapeutic
concentrations of lithium or valproate for 48 hr, then examined the
interaction between WFS1 and GRP94 by immunoprecipitation.
The amount of GRP94 co-immunoprecipitated with WFS1 was
decreased with lithium (Figure 3A, lanes 3 and 4, upper panels). The
amount of WFS1 immnoprecipitated with anti-WFS1 antibody was
also decreased with lithium (Figure 3A, lanes 3 and 4, lower panels,
IP). Figure 3B shows that lithium treatment of Neuro-2a cells did not
change the ratio between immunoprecipitated WFS1 and GRP94.
These results suggest that lithium treatment may cause a
conformational change of WFS1 protein, rendering the immuno-
precipiation with anti-native-WFS1 antibody less efficient.
Valproate increased WFS1 expression levels in a dose-
dependent manner (Figure 3A, lanes 5 and 6, lower panels,
input). A parallel rise was observed in the amount of immuno-
precipitated WFS1 (Figure 3A, lanes 5 and 6, lower panels, IP).
Valproate decreased the ratio between immunoprecipiated WFS1
and GRP94 in a dose-dependent manner (Figure 3B), suggesting
that WFS1 dissociates from GRP94 and that GRP94-free WFS1 is
increased with valproate.
Discussion
Although it is well established that valproate is a standard
treatment for bipolar disorder and a first-line mood stabilizer, its
mechanism of action has not been fully elucidated. Our results
demonstrate that valproate induces expression of WFS1 and
Figure 2. WFS1 promoter is activated by valproate. SH-SY5Y cells
were transfected with a reporter plasmid containing 500 bases of the
WFS1 promoter driving the luciferase gene (pGL3-WFS1-long), a control
reporter plasmid containing only 60 bases of the WFS1 promoter (pGL3-
WFS1-short), or control plasmid (pGL3) plus XBP-1 expression plasmid
or control plasmid. The cells were then treated with two different
concentrations of valproate, 50 mg/ml and 200 mg/ml, for 6 hr.
doi:10.1371/journal.pone.0004134.g002
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that the therapeutic effect of valproate is partially mediated by
modulation of ER stress through the regulation of WFS1 and
GRP94.
Valproate strongly activates the promoter region of WFS1 gene.
We have previously shown that the minimum element for WFS1
promoter activation under ER stress conditions. The sequence of
the element was similar to the one of ER stress response element
(ERSE). We called it ERSE-like element [22]. The upregulation of
WFS1 by valproate is probably regulated by the same element
because the promoter lacking this sequence, pGL3-WFS1-short,
did not respond to valproate (Figure 2). Consistent with previous
results, this activation can be enhanced by co-transfection of the
transcription factor XBP-1. It is possible that this activation might
be indirect because our previous result indicated that XBP-1 could
not directly bind to the ERSE-like element [22]. Other unknown
transcription factors induced by XBP-1 or interacted with XBP-1
may have a function in the activation of WFS1 promoter.
High-throughput proteomics analysis revealed that GRP94 was
one of the proteins that could interact with WFS1 in 293T cells
(Fonseca and Urano, manuscript in preparation). Our data
indicate that valproate enhances dissociation of WFS1 from
GRP94. Considered collectively, valproate may regulate the UPR
by modulating the interaction between GRP94 and WFS1.
Figure 3. Mood stabilizers modulate the WFS1-GRP94 complex. (A) Neuro-2a cells were treated with lithium (Li, 0.5 mM, 1 mM), valproate
(VPA, 50 ug/ml, 100 ug/ml) for 48 hr or untreated. Wfs1 was immunoprecipitated (IP) using lysates from the cells with anti-Wfs1 antibody. IP products
were immunoblotted (IB) with anti-GRP94 antibody or anti-Wfs1 antibody. (B) The ratio of the relative amount of immunoprecipitaed GRP94 to that
of immunoprecipitated WFS1 is shown. The X axis indicates the concentration of each drug.
doi:10.1371/journal.pone.0004134.g003
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bipolar disorder in the Japanese population [14]. The protective
GRP94 allele associated with bipolar disorder was related to low
mRNA expression of GRP94 [14]. Downregulation of GRP94
may increase the amount of GRP94-free WFS1, leading to the
enhancement of WFS1 function. Thus, the downregulation of
GRP94 may have the same effect as the upregulation of WFS1. It
is also possible that upregulation of WFS1 by valproate increases
the ratio between GRP94-free WFS1 and GRP94-bound WFS1,
leading to the activation of WFS1 (Figure 4).
GRP94 is an ER resident member of the HSP90 family of
molecular chaperones. It has been shown that an HSP90 inhibitor,
geldanamycin, can bind to GRP94, inhibit its function, and
increase the transcription of ER molecular chaperones [24]. It
would be possible that geldanamycin as well as its less toxic
analogues, 17-AAG and GA, may synergize with valproate and
increase its effect on WFS1 expression and modulation of the
WFS1-GRP94 complex. Thus, inhibitors of GRP94 function
could be a novel class of drug for bipolar disorder.
In this study, we focused on the function of valproate in WFS1
expression and its interaction with GRP94. The modulation of ER
stress through the activation of WFS1 may be part of valproate’s
action in bipolar disorder. Our findings suggest that valproate and
a compound that can reduce GRP94 expression in neurons may
be a valuable treatment for patients with bipolar disorder.
Methods
Cell culture
Neuro-2a cells, SH-SY5Y, and 293T cells were maintained in
DMEM with 10% fetal bovine serum.
Immunoblotting and immunoprecipitation
Cell extracts were prepared by lysis in TNE buffer (50 mM
Tris-HCl pH7.5, 150 mM NaCl, 1 mM EDTA and 0.1% NP40)
containing protease inhibitors and phosphatase inhibitor Cocktail
2 (SIGMA) for 15 min on ice, then the extracts were cleared by
centrifuging at 12,000 g for 20 min at 4uC. Extracts were
normalized for total protein (10 mg per lane), separated using
4%–20% linear gradient SDS-PAGE (Bio Rad, Hercules, CA) and
electroblotted. Blots were probed with the following antibodies:
anti-actin (Sigma, St. Louis, MO); anti-phospho-eIF2a, anti-
GRP94 (Cell Signaling, Danvers, MA). The amount of protein was
quantified using ImageJ software. For the immunoprecipitation,
cells extracts were prepared by lysis in TNE buffer containing
protease inhibitors for 15 min on ice. WFS1 was immunoprecip-
itated from the extracts with anti-WFS1 antibody, a gift from Drs.
Hisamitsu Ishihara and Yoshitomo Oka (Tohoku University,
Japan).
Luciferase Assay
SH-SY5Y cells were transfected with a reporter plasmid
containing 500 bases of the WFS1 promoter driving the luciferase
gene (pGL3-WFS1-long), a control reporter plasmid containing
only 60 bases of the WFS1 promoter (pGL3-WFS1-short), or
control plasmid (pGL3) plus XBP-1 expression plasmid or control
plasmid using Lipofectamine
TM 2000 (Invitrogen, Carlsbad, CA).
48 hrs post-transfection, the cells were treated with two different
concentrations of valproate, 50 mg/ml and 200 mg/ml, for 6 hr
and then lysed using a Luciferase Assay System kit (Promega,
Madison, WI). The light produced from the samples was read by a
plate reading luminometer, Victor X (Perkin Elmer, Waltham,
MA). Each sample was read in triplicate and normalized against
the signal produced from mock wells.
Real-time polymerase chain reaction
Total RNA was isolated from the cells with the RNeasy Mini Kit
(Qiagen, Valencia, CA) and reverse transcribed using 1 mg of total
RNA from cells with Oligo-dT primer. For the thermal cycle
reaction, the iQ5 system (BioRad, Hercules, CA) was used at 95uC
for10 min,then 40 cyclesat95uCfor10 sec,and at 55uCfor30 sec.
The relativeamount for eachtranscript wascalculated by a standard
curve of cycle thresholds for serial dilutions of cDNA sample and
normalized to the amount of actin. The polymerase chain reaction
(PCR) was done in triplicate for each sample, then all experiments
were repeated three times. The following sets of primers and Power
SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA) were used for real-time PCR: for mouse actin, GCAAGTGC-
TTCTAGGCGGAC and AAGAAAGGGTGTAAAACGCAGC;
for mouse WFS1, CCATCAACATGCTCCCGTTC and GGGT-
AGGCCTCGCCATACA; for mouse GRP94, AAGAATGAAG-
GAAAAACAGGACAAAA and CAAATGGAGAAGATTCC-
GCC; for mouse GRP78, TTCAGCCAATTATCAGCAAAC-
TCT and TTTTCTGATGTATCCTCTTCACCAGT; for mouse
total XBP-1, TGGCCGGGTCTGCTGAGTCCG and GTCC-
ATGGGAAGATGTTCTGG; for mouse spliced XBP-1, CTGA-
GTCCGAATCAGGTGCAG and GTCCATGGGAAATGTT-
CTGG; for mouse AATF, TTCTTGGCAAACCGGAGC and
AGCGTCTCTGGTTCTCCTGG.
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Figure 4. A speculative model of the action of valproate in the regulating of WFS1 and in the treatment of bipolar disorder.
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